Cadrenal Therape SEC Filings

CVKD NASDAQ

Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a biotech filing packed with clinical jargon can feel tougher than running a Phase 3 trial. Cadrenal Therapeutics’ disclosures are no exception—each 10-K details tecarfarin trial costs, orphan-drug milestones, and cash runway assumptions that are easy to miss. If you have ever searched for “Cadrenal Therapeutics SEC filings explained simply”, you already know the challenge.

Stock Titan solves it. Our AI converts dense pages into plain-English insights, flagging exactly where R&D spend shifts, insider dispositions surface, or pivotal trial data appear. Need the Cadrenal Therapeutics quarterly earnings report 10-Q filing or an 8-K material events explained? They post here in real time, and our summaries highlight liquidity updates and FDA correspondence. Form types we cover include:

10-K – Cadrenal Therapeutics annual report 10-K simplified so you can spot tecarfarin development timelines in minutes.
10-Q – Earnings report filing analysis with AI-generated trend charts.
8-K – Cadrenal Therapeutics 8-K material events explained, from trial halts to financing deals.
Form 4 – Cadrenal Therapeutics Form 4 insider transactions real-time, letting you track executive stock transactions before markets react.
DEF 14A – Proxy statement executive compensation breakdowns.

Whether you are investigating Cadrenal Therapeutics insider trading Form 4 transactions, comparing cash burn between quarters, or simply understanding Cadrenal Therapeutics SEC documents with AI, Stock Titan equips you with expert analysis, real-time alerts, and complete historical coverage. Make informed calls on CVKD without digging through hundreds of pages.

07/18/2025 04:49 PM

Filing

[8-K] Cadrenal Therapeutics, Inc. Reports Material Event

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Cadrenal Therape (CVKD)?

The current stock price of Cadrenal Therape (CVKD) is $11.29 as of July 18, 2025.

What is the market cap of Cadrenal Therape (CVKD)?

The market cap of Cadrenal Therape (CVKD) is approximately 25.6M.

What is the primary focus of Cadrenal Therapeutics?

Cadrenal Therapeutics is focused on developing tecarfarin, a novel oral anticoagulant designed to address unmet needs in chronic anticoagulation for patients with implanted cardiac devices and rare cardiovascular conditions.

How does tecarfarin differ from traditional anticoagulants?

Tecarfarin is designed using a unique metabolism pathway that is different from warfarin, leading to fewer drug-drug interactions, more stable anticoagulation, and improved management of patients with renal impairment.

Which patient segments are targeted by tecarfarin?

Tecarfarin targets patients who require chronic anticoagulation, including those with left ventricular assist devices (LVADs), end-stage renal disease on dialysis, atrial fibrillation, and other rare cardiovascular conditions.

What regulatory designations has tecarfarin received?

Tecarfarin has received Orphan Drug and Fast-Track designations from the FDA, highlighting its potential to address critical unmet medical needs in specific patient populations.

What role do strategic partnerships play in Cadrenal’s development strategy?

Strategic discussions with industry leaders, such as Abbott, enhance the company’s ability to conduct pivotal clinical trials and potentially streamline the development and adoption process of tecarfarin in targeted patient populations.

How has the efficacy of tecarfarin been evaluated?

Tecarfarin has been evaluated in numerous clinical trials, including Phase 1, Phase 2, and Phase 2/3 studies, with data indicating improved time in therapeutic range (TTR) and a favorable tolerability profile even in patients with complex conditions.

What distinguishes Cadrenal Therapeutics in the anticoagulation market?

The company distinguishes itself through its focus on an innovative metabolic pathway for anticoagulation, addressing the shortcomings of warfarin and providing a targeted solution for patients with complex, high-risk conditions.

Are there any particular challenges that tecarfarin aims to overcome?

Yes, tecarfarin aims to overcome challenges such as variable dosing, frequent monitoring, drug-drug interactions, and the instability of conventional anticoagulants, offering a potentially more reliable and predictable alternative for patients.

Cadrenal Therape

NASDAQ:CVKD

CVKD Rankings

#8010 Ranked by Market Cap

N/A Ranked by Dividends

CVKD Stock Data

Market Cap 25.57M

Float 1.39M

Insiders Ownership 30.69%

Institutions Ownership 5.65%

Short Percent 1.65%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City PONTE VEDRA